Kostiantyn O. Yushko

Kostiantyn O. Yushko

Auto-generated profile, based on publicly available information

Kostiantyn O. Yushko

State Institution “L.T. Malaya National Therapy Institute of the National Academy of Medical Science of Ukraine”, Kharkiv, Ukraine

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2019 in Arterial Hypertension
Verified
Journal Article
Open access
PDF file
SKSergiy M. Koval
Sergiy M. Koval
KYKostiantyn O. Yushko
Kostiantyn O. Yushko
ISIryna O. Snihurska
Iryna O. Snihurska
TSTetyana G. Starchenko
Tetyana G. Starchenko
VPVolodymyr Pankiv
Volodymyr Pankiv
OMOlga V. Mysnychenko
Olga V. Mysnychenko
Background. The angiotensin-(1-7) is a new component of the renin-angiotensin system, the product of the degradation of angiotensin II and its functional antagonist, but its role in hypertension with type 2 diabetes (T2D) is not clear. The aim of the study was to investigate the levels of angiotensin-(1-7) in patients with hypertension and T2D and determine its relations to hemodynamic and cardiac structural and functional parameters. Material and methods. We examined 70 patients with hypertension and T2D. Investigation protocol included physical examination, standard transthoracic echocardiography and determination of the angiotensin-(1-7) blood levels by ELISA. Control group consisted of 16 healthy volunteers. Results. The angiotensin-(1-7) levels in observed patients were significantly lower than in volunteers [105.51 (89.13;121.17) ng/L vs. 132.75 (125.06; 142.87) ng/L, p < 0.001]. The levels of the angiotensin-(1-7) significantly negatively correlated with duration of hypertension (r = –0.29, p < 0.05), systolic blood pressure (BP) (r = –0.38, p < 0.05), diastolic BP (r = –0.36, p < 0.01), average BP (r = –0.32, p < 0.01), left ventricular (LV) internal dimension at end-diastole (r = –0.37, p < 0.01), LV mass (r = –0.40, p < 0.001), LV mass index (r = –0.41, p < 0.001). In patients with LV hypertrophy, angiotensin-(1-7) levels were significantly lower than in patients without LV hypertrophy [101.9 (88.2; 117.7) ng/L vs. 129.3 (117.5; 136.8) ng/L, p < 0.01] and in patients with diastolic LV dysfunction — lower than in the patients with normal diastolic function [101.1 (87.9; 116.6) ng/L vs. 121.1 (105.5; 128.9) ng/L, p < 0.01]. Conclusions. The angiotensin-(1-7) can be considered as an important pathogenetic factor in the development of hypertension with T2D, a BP regulator and a cardioprotective agent that prevents the development of remodeling and diastolic dysfunction of the LV. Background. The angiotensin-(1-7) is a new component of the renin-angiotensin system, the product of the degradation of angiotensin II and its functional antagonist, but its role in hypertension with type 2 diabetes (T2D) is not clear. The aim of the study was to investigate the levels of angiotensin-(1-7) in patients with hypertension and T2D and determine its relations to hemodynamic and cardiac structural and functional parameters. Material and methods. We examined 70 patients with hypertension and T2D. Investigation protocol included physical examination, standard transthoracic echocardiography and determination of the angiotensin-(1-7) blood levels by ELISA. Control group consisted of 16 healthy volunteers. Results. The angiotensin-(1-7) levels in observed patients were significantly lower than in volunteers [105.51 (89.13;121.17) ng/L vs. 132.75 (125.06; 142.87) ng/L, p < 0.001]. The levels of the angiotensin-(1-7) significantly negatively correlated with duration of hypertension (r = –0.29, p < 0.05), systolic blood pressure (BP) (r = –0.38, p < 0.05), diastolic BP (r = –0.36, p < 0.01), average BP (r = –0.32, p < 0.01), left ventricular (LV) internal dimension at end-diastole (r = –0.37, p < 0.01), LV mass (r = –0.40, p < 0.001), LV mass index (r = –0.41, p < 0.001). In patients with LV hypertrophy, angiotensin-(1-7) levels were significantly lower than in patients without LV hypertrophy [101.9 (88.2; 117.7) ng/L vs. 129.3 (117.5; 136.8) ng/L, p < 0.01] and in patients with diastolic LV dysfunction — lower than in the patients with normal diastolic function [101.1 (87.9; 116.6) ng/L vs. 121.1 (105.5; 128.9) ng/L, p < 0.01]. Conclusions. The angiotensin-(1-7) can be considered as an important pathogenetic factor in the development of hypertension with T2D, a BP regulator and a cardioprotective agent that prevents the development of remodeling and diastolic dysfunction of the LV.

22 November 2019 in Biomedical Research and Therapy
Verified
Journal Article
Open access
PDF file
SKSergiy M. Koval
Sergiy M. Koval
ISIryna O. Snihurska
Iryna O. Snihurska
TSTetyana G. Starchenko
Tetyana G. Starchenko
MPMarina Yu. Penkova
Marina Yu. Penkova
OMOlga V. Mysnychenko
Olga V. Mysnychenko
Alexander E. BerezinAlexander E. Berezin
Alexander E. Berezin
Background: Arterial hypertension (AH) remains the most common cardiovascular (CV) risk factor worldwide. Methods: Seventy five moderate-to-severe hypertensive patients with abdominal obesity aged from 48 to 66 years (45/30 men and women respectively) were selected from the entire cohort (n = 375) according to the inclusion and exclusion criteria. The patients were divided into two subgroups depending on the arm of antihypertensive therapy lines. The first subgroup of patients (n = 36) received a non-fixed combination of oral antihypertensive agents: perindopril (4–8 mg daily), indapamide (1.25–2.5 mg daily) and amlodopine (5–10 mg daily). The second subgroup of patients (n=39) received fixed-dosed combination of these antihypertensive agents aforementioned in the ranged doses (4 mg/1.25mg/5 mg; 4 mg/1.25mg/10 mg; 8 mg/2.5 mg/5 mg; 8 mg/2.5mg/10 mg) in the same manner. The examinations of the clinical status, office, and ambulatory blood pressure values were carried out at baseline in 3 and 6 months after study entry. Results: The frequencies of BP target levels after treatment were higher in the fixed-dose combination group than in the non-fixed combination (at 3 months: 80% versus 58%, p<0.05 and at 6 months: 85% versus 53%, p<0.05). The adherence to triple fixed-dose combination was also higher in comparison with one to non-fixed combination (at 3 months: 82% versus 64%, p<0.05 and at 6 months: 87% versus 61%, p<0.05). It has been established that low-dose of perindopril/indapamide/amlodopine (4mg/1.25/10mg and 8mg/2.5/5mg) were used frequently in fixed-dose combination cohort of patients than in non-fixed combination (15% versus 0%, P<0.05, and 33% versus 19%, p<0.05, respectively). At the same time, maximum doses of these agents (8mg/2.5mg/10mg) were required for achieving target BP levels in a significantly lower proportion of patients receiving fixed-dose combination as compared to patients receiving non-fixed combination (52% versus 81%, p<0.05). Additionally, the triple fixed-dose combination has proved to be better in restoring ambulatory blood pressure monitoring profile than non-fixed combination. Conclusion: Achievement of target blood pressure levels in patients with uncontrolled arterial hypertension and abdominal obesity was possible at lower doses of perindopril, indapamide, and amlodipine when used as a fixed-dose combination rather than non-fixed (free) combination.

1 May 2019
Verified
Journal Article
Closed access
SKSergiy Koval
Sergiy Koval
ISI Snihurska
I Snihurska
KYKostiantyn Yushko
Kostiantyn Yushko
OLOlga Lytvynova
Olga Lytvynova
Alexander E. BerezinAlexander E. Berezin
Alexander E. Berezin

1 December 2021 in Pathologia
Verified
Journal Article
Open access
PDF file
СКС. М. Коваль
С. М. Коваль
ISI. O. Snihurska
I. O. Snihurska
KYK. O. Yushko
K. O. Yushko
OMO. V. Mysnychenko
O. V. Mysnychenko
VHV. Yu. Halchynska
V. Yu. Halchynska
Мета роботи – вивчити особливості складу мікробіоти кишечника (МК) у хворих на артеріальну гіпертензію (АГ), яка перебігає на тлі абдомінального ожиріння (АО). Матеріали та методи. Наведено результати обстеження 70 хворих на АГ 2–3 ступенів (46 пацієнтів з АО, 24 без ожиріння – з нормальною масою тіла (НМТ)). Група контролю включала 20 практично здорових осіб із НМТ. Хворим здійснили детальне клінічне, лабораторне й інструментальне обстеження. Кількісний склад МК визначали методом полімеразної ланцюгової реакції з гібридизаційно-флуоресцентною детекцією результатів у режимі реального часу з використанням тест-системи «КОЛОНОФЛОР-16 (біоценоз)» («АЛЬФА-ЛАБ»). Статистичний аналіз результатів виконали за допомогою Microsoft Exсel 17.0, використали стандартні методи. Результати. Встановили суттєві зміни складу МК у пацієнтів з АГ, що перебігає на тлі АО, порівняно з практично здоровими особами та хворими на АГ без ожиріння (з НМТ). У групі хворих на АГ з АО виявили вірогідне зменшення кількості Lactobacillus spp., Bifidobacterium spp., Faecalibacterium prausnitzii і Аkkermansia muciniphila порівняно з практично здоровими особами. Кількість Faecalibacterium prausnitzii і Аkkermansia muciniphila у цих пацієнтів також вірогідно нижча, ніж у хворих на АГ із НМТ. Співвідношення Bacteroides fragilis/Faecalibacterium prausnitzii вірогідно вище, ніж у групі контролю та групі хворих з АГ без ожиріння (з НМТ). Висновки. Результати дослідження вказують на можливу роль дефіциту таких представників МК, як Lactobacillus spp., Bifidobacterium spp., Faecalibacterium prausnitzii, Аkkermansia muciniphila та підвищення показника співвідношення Bacteroides fragilis/Faecalibacterium prausnitzii в патогенезі АГ, що перебігає на тлі АО.

23 May 2018 in HYPERTENSION
Verified
Journal Article
Open access
PDF file
SKS.M. Koval
S.M. Koval
ISI.O. Snihurska
I.O. Snihurska
MPM.YU. Penkova
M.YU. Penkova
OLO.M. Lytvynova
O.M. Lytvynova
VBV.V. Bozhko
V.V. Bozhko
KYK.O. Yushko
K.O. Yushko
Подано огляд даних літератури щодо лікування артеріальної гіпертензії у хворих на цукровий діабет. Розглянуто сучасні підходи до медикаментозного лікування артеріальної гіпертензії у цієї категорії хворих. Наведено детальну характеристику основних антигіпертензивних препаратів, які рекомендовані для адекватного контролю артеріального тиску у хворих на цук-ровий діабет.

1 January 2014 in Research Result. MEDICINE AND PHARMACY SERIES
Verified
Journal Article
Closed access
MTMalaya L.T. National Institute of Therapy
Malaya L.T. National Institute of Therapy
SKS.N. Koval
S.N. Koval
KYK.A. Yushko
K.A. Yushko
TST.G. Starchenko
T.G. Starchenko